Massimo Di Maio, PhD, medical oncologist, Mauriziano Hospital, professor of medical oncology, University of Turin, discusses the importance of quality of life (QoL) endpoints in clinical trials.
Massimo Di Maio, PhD
Advertisement
Articles by Massimo Di Maio, PhD
Advertisement
Latest Updated Articles
Importance of Quality of Life Endpoints in Clinical TrialsPublished: May 10th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5